USPTO Backlog Impacts Biopharma Industry

Unless Situation Is Resolved, Investment in New Candidates May Be Delayed or Withheld

Large pharmaceutical companies are increasingly turning to smaller biotechnology and pharmaceutical companies to supplement their drug development pipelines. When deciding whether to invest in a start-up or smaller firm, the acquiring company faces two major uncertainties: (1) Will a promising early-stage compound gain approval from the FDA? and (2) ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

User Input
Do not put any letters or characters here if you are not a spy program.